comprehensive -WSS

comprehensive

author：explore 2025-08-12 08:28:17 - browse：83

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Do digital therapeutics have a future in medicine?

entertainment

WSS

Cognito secures funding to test medical device for Alzheimer's

How dance can help health care workers heal from trauma

Man who had jail sentence commuted by Trump arrested again

The kidney, in all its complexity, is captured in a new atlas

Woodcock on FDA’s accelerated approval and her next chapter

Commercial surrogacy can be ethical, despite pope’s claims

focus

comprehensive

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

How to save PrEP access — and even expand it

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Heart attack and stroke risk calculators need revising

Seattle police shoot person suspected in downtown stabbing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New warning issued for rebooking air travel after delays, cancellations

In Memoriam: Notable people who died in 2023

Novo Nordisk to expand supply of Wegovy for U.S. patients

hotspot

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

The real point of Kenneth Smith’s execution by nitrogen gas

SAMSHA loosens regulations on methadone treatment centers

hotspot

explore

entertainment

focus